Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2007-04-10
2007-04-10
Zucker, Paul A. (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S531000, C514S534000, C514S537000, C514S563000
Reexamination Certificate
active
11125710
ABSTRACT:
The present invention relates to novel thyroid receptor ligands and, more particularly, relates to malonamic acids and derivatives thereof of Formula I, which are useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, hypercholesteremia, depression, osteoporosis and hair loss. The present invention also provides methods, pharmaceutical compositions and kits for treating such diseases and disorders
REFERENCES:
patent: 4069343 (1978-01-01), Sellstedt et al.
patent: 4554290 (1985-11-01), Böger et al.
patent: 4766121 (1988-08-01), Ellis et al.
patent: 4826876 (1989-05-01), Ellis et al.
patent: 4910305 (1990-03-01), Ellis et al.
patent: 5061798 (1991-10-01), Emmett et al.
patent: 5232947 (1993-08-01), Sato et al.
patent: 5284971 (1994-02-01), Walker et al.
patent: 5401772 (1995-03-01), Yokoyama et al.
patent: 5569674 (1996-10-01), Yokoyama et al.
patent: 5654468 (1997-08-01), Yokoyama et al.
patent: 2 348 159 (2000-04-01), None
patent: 0580550 (1994-01-01), None
patent: 1033364 (2000-09-01), None
patent: WO 0058279 (1999-03-01), None
patent: WO 0007972 (2000-02-01), None
patent: WO 0039077 (2000-07-01), None
patent: WO 0051971 (2000-09-01), None
patent: WO 0058279 (2000-10-01), None
patent: WO 0072810 (2000-12-01), None
patent: WO 0072811 (2000-12-01), None
patent: WO 0072812 (2000-12-01), None
patent: WO 0072813 (2000-12-01), None
patent: WO 0072920 (2000-12-01), None
patent: WO 0073292 (2000-12-01), None
A. H. Underwood, et al., Nature, vol. 324, pp. 425-429, Dec. 4, 1986, “A Thyromimetic That Decreases Plasma Cholesterol Levels Without Increasing Cardiac Activity”.
N. Yokoyama, et al.,J. Med. Chem.1995, 38, pp. 695-707, “Synthesis and Structure—Activity Relationships of Oxamic Acid and Acetic Acid Derivatives Related toL-Thyronine”.
R. E. Steele, et al., International Congressional Service (Atheroscertosis X), 106:321-324 (1995), “CGS 26214, The Thyroxine Connection Revisited”.
Z. F. Stephan, et al., Atheroscierosis 126 (1996) pp. 53-63, “Demonstration of Potent Lipid-Lowering Activity by a Thyromimetic Agent Devoid of Cardiovascular and Thermogenic Effects”.
D. M. T. Chan, et al., Tetrahedron Letters 39 (1998), pp. 2933-2936, “New N- and O-Arylations with Phenylboronic Acids and Cupric Acetate,”.
A. H. Taylor, et al., Molecular Pharmacology, 52:542-547 (1997), “Beneficial Effects of a Novel Thyromimetic on Lipoprotein Metabollsm”.
J. L. Stanton, et al., Bioorganic & Medicinal Chemistry Letters 10 (2000), pp. 1661-1663, “Synthesis and Biological Activity of Phenoxyphenyl Oxamic Acid Derivatives Related toL-Thyronine”.
U.S. Appl. No. 09/671,668.
U.S. Appl. No. 60/177,987.
Aspnes Gary E.
Chiang Yuan-Ching P.
Estep Kimberly G.
Ashbrook Charles W.
Baude Eric J.
Dixon J. Michael
Warner Lambert Company LLC
Zucker Paul A.
LandOfFree
Malonamic acids and derivatives thereof as thyroid receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Malonamic acids and derivatives thereof as thyroid receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Malonamic acids and derivatives thereof as thyroid receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3793286